In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grelan Pharmaceuticals Ltd.

Division of ASKA Pharmaceutical Co. Ltd.

Latest From Grelan Pharmaceuticals Ltd.

Fournier's European Strategy

To reduce its dependence on a stagnant and price sensitive French market, Fournier has created a low-risk R&D program coupled with an aggressive international acquisition program. The program attempts to take advantage of small-market research opportunities as well as acquisition targets overlooked by large companies or which fall out of mega-mergers. Is this gamble enough to ensure independence for a mid-sized player?
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • ASKA Pharmaceutical Co. Ltd.
  • Senior Management
  • Akira Yanagisawa, Pres. & CEO
  • Contact Info
  • Grelan Pharmaceuticals Ltd.
    Phone: (81) 3 3281 1451
    3-14-1 Nihonbashi, Chuo-ku
    Tokyo, 103
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register